957 related articles for article (PubMed ID: 8691638)
21. bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time.
Ohsaki Y; Toyoshima E; Fujiuchi S; Matsui H; Hirata S; Miyokawa N; Kubo Y; Kikuchi K
Clin Cancer Res; 1996 May; 2(5):915-20. PubMed ID: 9816250
[TBL] [Abstract][Full Text] [Related]
22. Relationship of p53 alteration and myc family gene overexpression with the clinical characteristics of lung cancer.
Bai L; Sun Y; Li S
Chin Med J (Engl); 1997 Apr; 110(4):250-4. PubMed ID: 9594222
[TBL] [Abstract][Full Text] [Related]
23. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.
Okano T; Gemma A; Hosoya Y; Hosomi Y; Nara M; Kokubo Y; Yoshimura A; Shibuya M; Nagashima M; Harris CC; Kudoh S
Oncol Rep; 2006 Mar; 15(3):545-9. PubMed ID: 16465410
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance.
Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
Pol J Pathol; 2006; 57(3):149-59. PubMed ID: 17219742
[TBL] [Abstract][Full Text] [Related]
25. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions.
Dimitrakakis C; Kymionis G; Diakomanolis E; Papaspyrou I; Rodolakis A; Arzimanoglou I; Leandros E; Michalas S
Gynecol Oncol; 2000 Apr; 77(1):129-36. PubMed ID: 10739702
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma.
Allal AS; Waelchli L; Bründler MA
Clin Cancer Res; 2003 Dec; 9(17):6489-96. PubMed ID: 14695153
[TBL] [Abstract][Full Text] [Related]
27. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
[TBL] [Abstract][Full Text] [Related]
28. Expression in lung carcinomas of platelet-derived growth factor and its receptors.
Kawai T; Hiroi S; Torikata C
Lab Invest; 1997 Nov; 77(5):431-6. PubMed ID: 9389786
[TBL] [Abstract][Full Text] [Related]
29. A novel molecular staging protocol for non-small cell lung cancer.
Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
[TBL] [Abstract][Full Text] [Related]
30. High frequency of frameshift mutation on p53 gene in Taiwanese with non small cell lung cancer.
Chang MY; Chong IW; Chen FM; Wang JY; Cheng TL; Cheng YJ; Sheu CC; Hung SY; Yang MC; Lin SR
Cancer Lett; 2005 May; 222(2):195-204. PubMed ID: 15863268
[TBL] [Abstract][Full Text] [Related]
31. [Human papillomavirus infection and p53 gene mutation in primary lung cancer].
Da J; Chen L; Hu Y
Zhonghua Zhong Liu Za Zhi; 1996 Jan; 18(1):27-9. PubMed ID: 8732107
[TBL] [Abstract][Full Text] [Related]
32. Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation.
Jiang SX; Kameya T; Sato Y; Yanase N; Yoshimura H; Kodama T
Am J Pathol; 1996 Mar; 148(3):837-46. PubMed ID: 8774138
[TBL] [Abstract][Full Text] [Related]
33. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer.
Giatromanolaki A; Koukourakis MI; Kakolyris S; Turley H; O'Byrne K; Scott PA; Pezzella F; Georgoulias V; Harris AL; Gatter KC
Clin Cancer Res; 1998 Dec; 4(12):3017-24. PubMed ID: 9865915
[TBL] [Abstract][Full Text] [Related]
34. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
35. p53 alterations in plutonium-induced F344 rat lung tumors.
Kelly G; Stegelmeier BL; Hahn FF
Radiat Res; 1995 Jun; 142(3):263-9. PubMed ID: 7761575
[TBL] [Abstract][Full Text] [Related]
36. Application of the p53 gene mutation pattern for differential diagnosis of primary versus metastatic lung carcinomas.
Noguchi M; Maezawa N; Nakanishi Y; Matsuno Y; Shimosato Y; Hirohashi S
Diagn Mol Pathol; 1993 Mar; 2(1):29-35. PubMed ID: 8287223
[TBL] [Abstract][Full Text] [Related]
37. Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations.
Volm M; Efferth T; Mattern J
Anticancer Res; 1992; 12(1):11-20. PubMed ID: 1348920
[TBL] [Abstract][Full Text] [Related]
38. Alterations of p53 gene in primary gastric cancer tissues.
Hong SI; Hong WS; Jang JJ; Lee DS; Cho NS; Jung ME; Kim HB; Ha GW; Park IC; Cho DS
Anticancer Res; 1994; 14(3B):1251-5. PubMed ID: 8067692
[TBL] [Abstract][Full Text] [Related]
39. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma.
Törmänen U; Eerola AK; Rainio P; Vähäkangas K; Soini Y; Sormunen R; Bloigu R; Lehto VP; Pääkkö P
Cancer Res; 1995 Dec; 55(23):5595-602. PubMed ID: 7585640
[TBL] [Abstract][Full Text] [Related]
40. Genetic alterations of tumor suppressor ING1 in human non-small cell lung cancer.
Luo ZG; Tang H; Li B; Zhu Z; Ni CR; Zhu MH
Oncol Rep; 2011 Apr; 25(4):1073-81. PubMed ID: 21286670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
